Application of Polychromatic Flow Cytometry to Identify Novel Subsets of Circulating Cells with Angiogenic Potential

被引:65
作者
Estes, Myka L. [1 ]
Mund, Julie A. [1 ,2 ]
Mead, Laura E. [1 ]
Prater, Daniel N. [1 ]
Cai, Shanbao [1 ]
Wang, Haiyan [1 ]
Pollok, Karen E. [1 ,2 ]
Murphy, Michael P. [3 ]
An, Caroline S. T. [4 ]
Srour, Edward F. [1 ,2 ,5 ]
Ingram, David A., Jr. [1 ,2 ,6 ]
Case, Jamie [1 ,2 ]
机构
[1] Indiana Univ, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46204 USA
[2] Indiana Univ, Melvin & Bren Simon Canc Ctr, Dept Hematol Oncol, Indianapolis, IN 46204 USA
[3] IU Methodist Riley, Dept Surg, Indianapolis, IN USA
[4] IU Methodist Riley, Dept Pathol, Indianapolis, IN USA
[5] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA
[6] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA
关键词
polychromatic flow cytometry; circulating progenitor cells; endothelial progenitor cells; angiogenesis; peripheral arterial disease; ENDOTHELIAL PROGENITOR CELLS; PRACTICAL APPROACH; CORD BLOOD; POPULATION;
D O I
10.1002/cyto.a.20921
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Defining whether human circulating proangiogenic cells represent a subset of the hematopoietic system and express CD45 or are hematopoietic derivatives that do not express CD45 (and are called endothelial progenitor cells) remains controversial. We have previously developed a polychromatic flow cytometry (PFC) protocol to isolate subsets of hematopoietic cells and we now identify the circulating pool of CD34(+)CD45(dim) cells representing functional circulating hematopoietic stem and progenitor cells (CHSPCs) that can be separated on the basis of AC133 expression and report that the AC133(+) subset of the CHSPCs enhances the growth of tumor blood vessels in vivo in immunodeficient mice. In addition, the ratio of AC133(+) proangiogenic CHSPCs to AC133(-) nonangiogenic CHSPCs unambiguously correlates with the severity of the clinical state of patients with peripheral arterial disease. In sum, a PFC protocol validated via in vitro and in vivo analyses, can be used to interrogate the roles of human hematopoietic elements in the growth and maintenance of the vasculature. (C) 2010 International Society for Advancement of Cytometry
引用
收藏
页码:831 / 839
页数:9
相关论文
共 30 条
[1]   A practical approach to multicolor flow cytometry for immunophenotyping [J].
Baumgarth, N ;
Roederer, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 243 (1-2) :77-97
[2]  
Bertolini F, 2003, CANCER RES, V63, P4342
[3]   The multifaceted circulating endothelial cell in cancer: towards marker and target identification [J].
Bertolini, Francesco ;
Shaked, Yuval ;
Mancuso, Patrizia ;
Kerbel, Robert S. .
NATURE REVIEWS CANCER, 2006, 6 (11) :833-845
[4]   Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors [J].
Case, Jamie ;
Mead, Laura E. ;
Bessler, Waylan K. ;
Prater, Daniel ;
White, Hilary A. ;
Saadatzadeh, M. Reza ;
Bhavsar, Janak R. ;
Yoder, Mervin C. ;
Haneline, Laura S. ;
Ingram, David A. .
EXPERIMENTAL HEMATOLOGY, 2007, 35 (07) :1109-1118
[5]   Homing and engraftment of progenitor cells: A prerequisite for cell therapy [J].
Chavakis, Emmanouil ;
Urbich, Carmen ;
Dimmeler, Stefanie .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2008, 45 (04) :514-522
[6]   Statistical criteria to establish optimal antibody dilution in flow cytometry analysis [J].
Collino, Cesar J. G. ;
Jaldin-Fincati, Javier R. ;
Chiabrando, Gustavo A. .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2007, 72B (03) :223-226
[7]   Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors [J].
De Palma, M ;
Venneri, MA ;
Galli, R ;
Sergi, LS ;
Politi, LS ;
Sampaolesi, M ;
Naldini, L .
CANCER CELL, 2005, 8 (03) :211-226
[8]   A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood [J].
Duda, Dan G. ;
Cohen, Kenneth S. ;
Scadden, David T. ;
Jain, Rakesh K. .
NATURE PROTOCOLS, 2007, 2 (04) :805-810
[9]   Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers [J].
Duda, Dan G. ;
Jain, Rakesh K. ;
Willett, Christopher G. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (26) :4033-4042
[10]  
ESTES ML, 2010, CURR PROTOC CYTOM, V9